-+ 0.00%
-+ 0.00%
-+ 0.00%

Xiansheng Pharmaceutical (02096): SIM0712 (STAT6) was issued a drug clinical trial approval notice by the State Drug Administration

Zhitongcaijing·11/16/2026 10:17:03
Listen to the news

Zhitong Finance App News, Xiansheng Pharmaceutical (02096) announced that SIM0712, an oral small molecule degradant with target signal transduction and transcription initiation factor 6 (“STAT6”) independently developed by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration to carry out clinical trials for the treatment of atopic dermatitis.